secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-09-14T20:00:15+00:00
Accession:  0001437749-26-030315
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin to present new Annamycin data at AACR pancreatic cancer conference and two European scientific meetings
--------------------------------------------------------------------------------

- Three September 2026 presentations examine Annamycin tissue distribution, topoisomerase II inhibition, and CD8+ T cell-mediated antitumor activity.
- Presentations include Sept 25-28 AACR Pancreatic Cancer Conference in San Diego, plus Polish meetings on Sept 9-12 and Sept 14.
- Waldemar Priebe (MD Anderson) presents two talks; Angela Alistar (Atlantic Health) presents AACR abstract on pancreatic cancer.
- MIRACLE trial in relapsed/refractory AML remains the primary development focus and basis of near-term milestones.
- AACR abstract under embargo until publication on Sept 25, 2026 at 1:00 p.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926030315/0001437749-26-030315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926030315/mbrx20260911_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-030315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer